Vireo Growth (VREOF) Other Non Operating Income (2020 - 2026)
Vireo Growth (VREOF) reported Other Non Operating Income of $100000.0 for Q1 2026, down 87.5% on a YoY basis from $800000.0 in Q1 2025, and up 106.5% sequentially from -$1.5 million in Q4 2025.
Vireo Growth (VREOF) Other Non Operating Income (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Other Non Operating Income data on file, last reported at $100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 87.5% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at -$862849.0 (down 299.87% YoY), and the FY2025 full-year result was -$172811.0, down 118.2% from the prior year.
- Other Non Operating Income rose to $100000.0 in Q1 2026, from -$1.5 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $5.8 million in Q2 2023 to a low of -$2.9 million in Q4 2024.
- A 5-year average of $580896.5 and a median of $345824.0 in 2023 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income soared 7105.44% in 2023 and sank 285.63% in 2024, its largest moves.
- Tracing VREOF's Other Non Operating Income over 5 years: stood at $45518.0 in 2022, then soared by 3370.77% to $1.6 million in 2023, then slumped by 285.63% to -$2.9 million in 2024, then soared by 47.55% to -$1.5 million in 2025, then surged by 106.5% to $100000.0 in 2026.
- Business Quant data shows VREOF's Other Non Operating Income at $100000.0 in Q1 2026, -$1.5 million in Q4 2025, and $983080.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -1.54 Mn |
| Sep 30, 2025 | 983,080.00 |
| Jun 30, 2025 | -407,673.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | -2.93 Mn |
| Sep 30, 2024 | 970,850.00 |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | 345,824.00 |
| Jun 30, 2023 | 5.80 Mn |
| Mar 31, 2023 | 22,313.00 |
| Dec 31, 2022 | 45,518.00 |
| Sep 30, 2022 | 79,750.00 |
| Jun 30, 2022 | -82,769.00 |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | -278,260.00 |
| Sep 30, 2021 | 75,018.00 |
| Jun 30, 2021 | -98,055.00 |